Skip to content
Kalpvruksh Markets
Offline Log in

SYMBIOTECNSEOffline

Symbiotec Pharmalab · INE899I01028
1,271.50+38.30 (+3.11%)last close · 05 Nov 2026
Prev close
1,233.20
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
—

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

SYMBIOTEC. Now under exchange surveillance.

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • MF schemes in Sept 2026: 21 bought, 25 cut · promoter pledge 38.5%
  • ASM short-term 1

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
2.1×
median 1,82,136
Delivered
3,77,918
Of volume
47%

Trading restrictions

Under surveillance
ASM short-term 1 (2026-11-13)

Price & trend

Price & trend

Not enough price historyFigures need 60 sessions of NSE prices.

Ownership

Who owns the company

% of all shares, by quarter

GroupMar 22Sep 26
Promoters25.1%33.3%
FPI0.0%3.8%
Mutual funds0.0%12.2%
Other DII0.0%20.6%
Individuals0.0%7.8%
Others74.9%22.4%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
38.5%
Of all shares
12.8%
Mar 22 0.0%Sep 26 38.5%

Holders

Sep 26

All shareholders
81,747
Individuals
78,783

Which funds bought and sold

No fund holds this companyNo Indian mutual fund disclosed a position at the last quarter end.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 2630714124+155.6%₹863 cr
Aug 264747000—₹284 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
Bought ₹0 (0)
Sold ₹11.88 cr (16)
Latest 0 of 16 disclosures

None in the latest 50 disclosures — switch to Everyone.

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Symbiotec Pharmalab Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    22 Sept 2026
  • Board outcome
    Symbiotec Pharmalab Limited has informed the Exchange regarding Outcome of Board Meeting held on September 21, 2026.
    22 Sept 2026
  • Bulk deal: SELL
    3,57,516 at ₹1,123.68 — JUNOMONETA FINSOL PRIVATE LIMITED
    02 Sept 2026
  • Bulk deal: BUY
    3,57,516 at ₹1,123.4 — JUNOMONETA FINSOL PRIVATE LIMITED
    02 Sept 2026
  • Bulk deal: SELL
    5,47,601 at ₹1,074.04 — ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED
    01 Sept 2026
  • Bulk deal: BUY
    5,52,698 at ₹1,074.1 — ELIXIR WEALTH MANAGEMENT PRIVATE LIMITED
    01 Sept 2026

Latest shown; 7 in six months on all disclosures.

SYMBIOTEC: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.